About Us

Sementis is an Australian unlisted public biotechnology company that is using its proprietary SCV platform. 

The Company is using its proprietary Sementis Copenhagen Vector (SCV) platform technology to generate a portfolio of innovative vaccine candidates for the prevention of allergies and infectious diseases. SCV is a novel vector platform that uses a replication-incompetent vaccinia virus to stimulate both B-cell and T-cell immune responses. The genes for disease antigens are added to the SCV, which upon inoculation elicits a potent immune response to the disease state. 

The Company’s product development strategy initially focuses on the development of a therapeutic peanut hypo-allergy vaccine for the treatment for peanut allergy and a Chikungunya preventative (prophylactic) vaccine. 

The technology has broad applications which can potentially lead to partnerships involving license fees based on achieving milestones and royalties.